The incidence of and mortality from both chronic obstructive pulmonary disease (COPD) and
cardiovascular disease (CVD) increase with age. In addition, the average age of patients …

Review is devoted to the place of β-adrenoblockers in the treatment of cardiovascular
disease (CVD) in patients with chronic obstructive pulmonary disease (COPD). Currently, it …

The prevalence of chronic obstructive pulmonary disease (COPD) continues to rise in
association with an aging Western society. While barriers to receiving optimal healthcare …

Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide
mortality. Presence of comorbidities is registered in 96% of COPD patients. The most …

Introduction The safety of β2-AR antagonists in the treatment of patients with COPD
continues to be a topic of research and discussion within the medical community. Emerging …

Heart failure (HF) is a major public health problem among the elderly. The syndrome of HF
may arise in the presence of either a depressed or apparently normal left-ventricular ejection …

Chronic heart failure (CHF) is a common and disabling condition with an incidence and
prevalence that increase sharply with age. The median age of presentation of new heart …

The common coexistence of chronic obstructive pulmonary disease (COPD) and
cardiovascular disease (CVD) presents several therapeutic constraints that have not been …

Chronic obstructive pulmonary disease is prevalent condition commonly associated with
cardiovascular diseases. When both are combined the prognosis of the patient worsens …

Purpose This study was undertaken to determine the association between cardiac function
and therapy with beta2-adrenoceptor agonists (β2-agonists), β-blockers, or β-blocker–β …